BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Neuropharm Group plc Sees Deal for Lead Drug, Shares Jump


5/28/2009 7:31:23 AM

Bookmark and Share

Neuropharm Group plc (AIM: NPH), a specialty pharmaceutical company focused on neurodevelopmental disorders, today announces an interim update to its shareholders on significant progress during the past three months.

On 18 February 2009 the Company announced the top-line results for the SOFIA study in Autistic Disorder of NPL-2008, a novel formulation of fluoxetine, which showed that this study had not met its primary endpoint of demonstrating a statistically significant difference between NPL-2008 and placebo treatment.

The Company has largely completed the analysis of the results from this study and is now in discussion with clinicians and experts in the field, who continue to express strong support for the product. In addition, following considerable interest in NPL-2008 from a number of parties, discussions have progressed well with a third party pharmaceutical company for a potential collaboration which would encompass the further development and commercialisation of NPL-2008. Neuropharm is therefore developing study designs for a second Phase III study, in conjunction with the partner.

Neuropharm’s intention would be to conduct a further Phase III study for NPL-2008 with a modified trial design, incorporating the important findings and insights from SOFIA, which will be funded through the collaboration. It is expected that a deal will be signed by the autumn of this year.

About Neuropharm

Neuropharm is a speciality pharmaceutical company focused on the development of medicines for the treatment and management of neurodevelopmental disorders. Please visit www.neuropharm.co.uk for further information.

Read at Reuters
Read at AFX Press
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES